Anhydrous enol oxaloacetate - MetVital
Alternative Names: AEO; Anhydrous Enol-Oxaloacetate; Anhydrous enol-oxaloacetate - MetVital; Oxaloacetate; Oxaloacetate CFSLatest Information Update: 28 Oct 2025
At a glance
- Originator MetVital
- Developer MetVital; Terra Biological
- Class Anti-inflammatories; Antidementias; Antineoplastics; Nootropics; Oxaloacetates; Small molecules
- Mechanism of Action Oxaloacetate replacements
-
Orphan Drug Status
Yes - Liver cancer; Glioblastoma; Amyotrophic lateral sclerosis
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Alzheimer's disease; Cognition disorders; Fatigue; Glioblastoma
- No development reported Amyotrophic lateral sclerosis; Liver cancer
Most Recent Events
- 28 Oct 2025 No recent reports of development identified for phase-I development in Amyotrophic-lateral-sclerosis in USA
- 27 Oct 2025 No development reported - Preclinical for Liver cancer in USA (unspecified route)
- 01 Jun 2023 Phase-II clinical trials in Fatigue in USA (unspecified route) (NCT05840237)